| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |